Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 6Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Advanced/Metastatic Solid Tumors 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × Trifluridine × Clear all
NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Emory University

Phase 1/2 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡